Limited efficiency coupled with off target adverse effects [22,23] have been seen in CAR-T cells targeting solid tumours, including renal carcinoma [22], neuroblastoma [53], ovarian cancer [54], and even ERBB2 positive breast cancer [23]. This evidence concerns the gene ERBB2 and breast carcinoma.